Skip to main content
Article thumbnail
Location of Repository

Increased cell motility and invasion upon knockdown of lipolysis stimulated lipoprotein receptor (LSR) in SW780 bladder cancer cells

By Malene Herbsleb, Karin Birkenkamp-Demtroder, Thomas Thykjaer, Carsten Wiuf, Anne-Mette K Hein, Torben F Ørntoft and Lars Dyrskjøt
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2492871
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2008). Amaxa http://www amaxa com
    2. (1994). Bihain BE: Identification of a lipolysisstimulated receptor that is distinct from the LDL receptor and the LDL receptor-related protein. Biochemistry
    3. (1997). Bihain BE: Inhibitory effects of specific apolipoprotein C-III isoforms on the binding of triglyceride-rich lipoproteins to the lipolysis-stimulated receptor.
    4. (1995). Bihain BE: Mechanism of activation and functional significance of the lipolysis-stimulated receptor. Evidence for a role as chylomicron remnant receptor. Biochemistry
    5. (2006). Cordon-Cardo C: Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays.
    6. (2001). Dey SK: Global gene expression analysis to identify molecular markers of uterine receptivity and embryo implantation.
    7. (2004). Distribution of the lipolysis stimulated receptor in adult and embryonic murine tissues and lethality of LSR-/- embryos at 12.5 to 14.5 days of gestation.
    8. (1995). ER: Modulation of transforming growth factor beta 1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix. Cancer Res
    9. (2005). FM: Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res
    10. (1992). FT: Free fatty acids activate a high-affinity saturable pathway for degradation of low-density lipoproteins in fibroblasts from a subject homozygous for familial hypercholesterolemia. Biochemistry
    11. (1995). FT: Inhibitory effect on the lipolysis-stimulated receptor of the 39-kDa receptor-associated protein.
    12. (1998). FT: The lipolysis stimulated receptor: a gene at last. Curr Opin Lipidol
    13. (2005). Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Clin Cancer Res
    14. (2001). Givol D: DNA microarrays identification of primary and secondary target genes regulated by p53. Oncogene
    15. (2001). GM: Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer.
    16. (2004). Irizarry RA: Preprocessing of oligonucleotide array data. Nat Biotechnol
    17. (2001). Koeffler HP: Breast cancer. Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease.
    18. (2006). MA: Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis
    19. (1999). Molecular cloning of a lipolysis-stimulated remnant receptor expressed in the liver.
    20. (2005). Orntoft TF: A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin Cancer Res
    21. (2005). Orntoft TF: Gene expression profiling of noninvasive primary urothelial tumours using microarrays.
    22. (2001). Orntoft TF: Identification of gene expression patterns in superficial and invasive human bladder cancer. Cancer Research
    23. (2003). Orntoft TF: Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet
    24. (2005). Orntoft TF: Secretagogin is a novel marker for neuroendocrine differentiation. Neuroendocrinology
    25. (2005). Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res
    26. (2003). PS: Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol
    27. (2005). Smad4 silencing in pancreatic cancer cell lines using stable RNA interference and gene expression profiles induced by transforming growth factorbeta. Oncogene
    28. (2003). Study of the alteration of gene expression in adipose tissue of diet-induced obese mice by microarray and reverse transcriptionpolymerase chain reaction analyses. Endocrinology
    29. (2006). The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including
    30. (2001). YJ: Initial sequencing and analysis of the human genome. Nature

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.